Fig. 3.

Monocyte phagocytosis is increased with HER2 gene-amplified targets. Antibody-dependent phagocytosis, degranulation, and tumor cell death were evaluated on HER2-amplified and -non-amplified tumor cell lines. a Titration curves of antibody-dependent phagocytosis, degranulation, and tumor cell death from SKBR3 (HER2 amplified) and T47D (HER2 non-amplified) tumor cell lines. All samples were performed in triplicate; means ± SEM and regression line are plotted on the graph. Two-way ANOVA with Sidak’s multiple comparisons test was used to determine significance. Asterisk represents significance between SKBR3 and T47D. b Comparison between antibody-dependent phagocytosis, degranulation, and tumor cell death of breast cancer cell lines that are amplified and non-amplified for HER2. Each point on the graph represents a different cell line and is the mean of a minimum of two experiments at the trastuzumab concentration of 316 ng/ml. Two tailed t tests were used to obtain P values for phagocytosis (P < 0.03), NK cell degranulation (P < 0.01), and tumor cell death (P > 0.8)